For most of the 20th century, clinical trials were conducted almost exclusively in men. The reasoning, that female hormonal variation complicated data and that biological insights from male subjects were universally applicable, was wrong. The consequences for women’s health have been significant.
The Historical Exclusion
Until 1993, the NIH did not require inclusion of women in federally funded clinical trials. The result was a medical literature built predominantly on male physiology, with drug dosing and safety profiles extrapolated from male subjects to female patients.
Consequences: – Women experience adverse drug reactions at approximately twice the rate of men, partly due to dosing optimized for male body composition – Heart attack symptoms in women, which differ significantly from the classic male presentation, were underrecognized for decades
What Changed
The NIH Revitalization Act of 1993 required inclusion of women and minorities in NIH-funded research. Modern clinical trial reporting now includes sex-disaggregated data as standard.
What Women Should Know About Modern Trial Participation
Pregnancy and trials. Most clinical trials exclude pregnant women for safety reasons. Participants who become pregnant are typically discontinued from study medication while continuing safety follow-up.
Hormone status matters. Many studies now collect data on menstrual cycle phase, contraceptive use, and menopausal status, recognizing that these variables affect drug pharmacokinetics and immune function.
Your data contributes to medicine for all women. Participating as a woman means contributing to evidence that will inform treatment for women specifically, not just extrapolations from male subjects.
NuLine welcomes participants of all genders across our clinical trial portfolio. See our current studies or apply today.